GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses
The circGPC3 cancer vaccine demonstrated superior efficacy compared with the mRNA cancer vaccine. When further combined with a TLR4 agonist, it disrupted immune tolerance in HCC, offering a promising translational treatment strategy for HCC.
Authors
- Chaofeng Ding
- Tong Wu (ORCID: https://orcid.org/0000-0003-3103-7909)
- Rongliang Tong (ORCID: https://orcid.org/0000-0002-4364-7950)
- Beng Yang
- Jiwei Liu (ORCID: https://orcid.org/0000-0002-4010-3026)
- Diyu Chen (ORCID: https://orcid.org/0000-0001-7424-1817)
- Yu Li (ORCID: https://orcid.org/0000-0001-9748-9364)
- Guangming Xu (ORCID: https://orcid.org/0000-0002-5147-3946)
- Jian Wu (ORCID: https://orcid.org/0000-0002-0882-072X)
- Yifan Jiang (ORCID: https://orcid.org/0000-0002-9737-2542)
- Linping Cao
- C.H. Hua (ORCID: https://orcid.org/0009-0001-4424-1039)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Fudan University (CN)
- Blood Center of Zhejiang Province (CN)
- Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
- Huashan Hospital (CN)
- Ministry of Public Health (MG)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Hepatology
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1097/hep.0000000000001605
- Citations
- 3
- Primary Topic
- Circular RNAs in diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.42